Stratos Wealth Partners’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History
Bought
Maintained
Sold
Other funds holding FTXH
Stratos Wealth Partners's FTXH Position: Q3 2026 in Review
Stratos Wealth Partners increased its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 8.6% in Q3 2026, buying an estimated $28.2K and bringing the position to 8,880 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.
Stratos Wealth Partners first reported a position in FTXH in Q3 2018 and has held it in 8 quarters since. 71 funds tracked by Wall St. Rank hold FTXH as of Q3 2026.
- Stratos Wealth Partners held 8,880 shares of First Trust Nasdaq Pharmaceuticals ETF worth $368K as of Q3 2026.
- Stratos Wealth Partners bought 700 First Trust Nasdaq Pharmaceuticals ETF shares in Q3 2026, an estimated $28.2K.
- First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q3 2026, its #1280 holding.
- Stratos Wealth Partners first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q3 2018 and has held it in 8 quarters since.
- 71 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2026.
Based on Stratos Wealth Partners's 13F filing for Q3 2026, filed 13 Nov 2026.